265 related articles for article (PubMed ID: 33741716)
1. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Sabbah M; Krayem M; Najem A; Sales F; Miller W; Del Rincon S; Awada A; Ghanem GE; Journe F
Mol Cancer Res; 2021 Jul; 19(7):1221-1233. PubMed ID: 33741716
[TBL] [Abstract][Full Text] [Related]
2. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
3. KIT
Phung B; Kazi JU; Lundby A; Bergsteinsdottir K; Sun J; Goding CR; Jönsson G; Olsen JV; Steingrímsson E; Rönnstrand L
Mol Cancer Res; 2017 Sep; 15(9):1265-1274. PubMed ID: 28584020
[TBL] [Abstract][Full Text] [Related]
4. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
[TBL] [Abstract][Full Text] [Related]
5. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
Todd JR; Becker TM; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
[TBL] [Abstract][Full Text] [Related]
6. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.
Laugier F; Delyon J; André J; Bensussan A; Dumaz N
Oncogene; 2016 Sep; 35(38):5070-7. PubMed ID: 26973244
[TBL] [Abstract][Full Text] [Related]
8. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
9. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
10. KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.
Lee YN; Brandal S; Noel P; Wentzel E; Mendell JT; McDevitt MA; Kapur R; Carter M; Metcalfe DD; Takemoto CM
Blood; 2011 Mar; 117(13):3629-40. PubMed ID: 21273305
[TBL] [Abstract][Full Text] [Related]
11. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
[TBL] [Abstract][Full Text] [Related]
12. C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation.
Phung B; Sun J; Schepsky A; Steingrimsson E; Rönnstrand L
PLoS One; 2011; 6(8):e24064. PubMed ID: 21887372
[TBL] [Abstract][Full Text] [Related]
13. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.
Javelaud D; Alexaki VI; Pierrat MJ; Hoek KS; Dennler S; Van Kempen L; Bertolotto C; Ballotti R; Saule S; Delmas V; Mauviel A
Pigment Cell Melanoma Res; 2011 Oct; 24(5):932-43. PubMed ID: 21801332
[TBL] [Abstract][Full Text] [Related]
14. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
15. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma.
Keenen B; Qi H; Saladi SV; Yeung M; de la Serna IL
Oncogene; 2010 Jan; 29(1):81-92. PubMed ID: 19784067
[TBL] [Abstract][Full Text] [Related]
18. KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM; Guhan S; Tsao H
Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
[TBL] [Abstract][Full Text] [Related]
19. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
Zhan Y; Guo J; Yang W; Goncalves C; Rzymski T; Dreas A; Żyłkiewicz E; Mikulski M; Brzózka K; Golas A; Kong Y; Ma M; Huang F; Huor B; Guo Q; da Silva SD; Torres J; Cai Y; Topisirovic I; Su J; Bijian K; Alaoui-Jamali MA; Huang S; Journe F; Ghanem GE; Miller WH; Del Rincón SV
J Clin Invest; 2017 Nov; 127(11):4179-4192. PubMed ID: 29035277
[TBL] [Abstract][Full Text] [Related]
20. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.
McGill GG; Horstmann M; Widlund HR; Du J; Motyckova G; Nishimura EK; Lin YL; Ramaswamy S; Avery W; Ding HF; Jordan SA; Jackson IJ; Korsmeyer SJ; Golub TR; Fisher DE
Cell; 2002 Jun; 109(6):707-18. PubMed ID: 12086670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
